Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.Financial_Report.xls
10-K - Arch Therapeutics, Inc.g6510.txt
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R26.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R27.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R13.htm
EX-32.1 - Arch Therapeutics, Inc.ex32-1.txt
EX-31.1 - Arch Therapeutics, Inc.ex31-1.txt
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R20.htm
v2.4.0.6
ALMAH,INC - (A Development Stage Company) - Statement of Operations (USD $)
12 Months Ended 36 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Revenues $ 0 $ 0 $ 0
Cost of Sales 0 0 0
Gross Margin 0 0 0
Operating Expenses      
General and Administrative Expense 36,611 5,037 41,648
Total Operating Expenses 36,611 5,037 41,648
Other Income 0 0 0
(Loss) Before Income Tax Expense (36,611) (5,037) (41,648)
Income Tax Expense 0 0 0
Net (Loss) $ (36,611) $ (5,037) $ (41,648)
Basic and Diluted Net Loss Per Share $ (0.01)    
Weighted Average Number of Common Shares Outstanding 4,684,082 1,073,973